Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.

Abstract

BACKGROUND Bisphosphonates, which are also known as osteoclast modifiers, are the standard of care in the treatment of skeletal-related events (SREs) in patients with breast cancer with metastatic bone disease. SREs are frequently a complication of advanced breast cancer, and they greatly increase morbidity and mortality in these patients. Unfortunately… (More)
DOI: 10.1188/15.CJON.E108-E114

Topics

  • Presentations referencing similar topics